<DOC>
	<DOCNO>NCT00933127</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This research study look blood tissue sample patient follicular lymphoma treat rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone .</brief_summary>
	<brief_title>S8809-S9800-S9911-S9704-A Study Blood Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab , Cyclophosphamide , Doxorubicin Hydrochloride , Vincristine , Prednisone</brief_title>
	<detailed_description>OBJECTIVES : - To test association polymorphism Fc-gamma ( Fcγ ) receptor IIa ( H/R131 ) IIIa ( V/F158 ) progression-free survival clinical response patient follicular non-Hodgkin lymphoma treat rituximab CHOP chemotherapy comprise cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone . - To assess novel polymorphism Fcγ receptor predictive prognostic significance patient treat regimen . OUTLINE : Genomic DNA extract paired sample serum formalin-fixed paraffin-embedded tissue analyze R131H polymorphism Fcγ receptor IIa V158F polymorphism Fcγ receptor IIIa TaqMan-based assay . The DNA also analyze genotype correspond several polymorphism Fcγ receptor , determine HapMap project . The result Fcγ receptor genotype compare clinical data Southwest Oncology Group database identify association particular genotype progression-free survival , overall response , complete response . A multivariate analysis incorporate clinical prognostic variable ( e.g. , age , stage , serum LDH level , extranodal disease , performance status ) also perform determine whether Fcγ receptor polymorphism independent predictive prognostic marker clinical outcome .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis follicular lymphoma Meets either follow criterion : Previously enrol clinical trial SW0G8809 treat chemotherapy alone Excess tissue section available Previously enrol clinical trial SWOG9800 SWOG9911 treat combination chemotherapy monoclonal antibody therapy Matched serum tissue sample available SWOG Lymphoma Bank PATIENT CHARACTERISTICS : See Disease Characteristics PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>